TY - JOUR T1 - Circulating Microparticles in Breast Cancer Patients: A Comparative Analysis with Established Biomarkers JF - Anticancer Research JO - Anticancer Res SP - 1107 LP - 1112 VL - 28 IS - 2A AU - BETTINA TOTH AU - RIENK NIEUWLAND AU - SUSANNE LIEBHARDT AU - NINA DITSCH AU - KERSTIN STEINIG AU - PETRA STIEBER AU - ANDREAS RANK AU - PETER GĂ–HRING AU - CHRISTIAN J. THALER AU - KLAUS FRIESE AU - INGO BAUERFEIND Y1 - 2008/03/01 UR - http://ar.iiarjournals.org/content/28/2A/1107.abstract N2 - Background: The aim of the present prospective case-control study was to evaluate the putative relevance of circulating microparticles (MP) as a biomarker in breast cancer patients. Materials and Methods: Endothelial cell-(EMP) and leukocyte-derived MP (LMP) were determined by flow cytometry in breast cancer patients (n=41) and healthy controls (n=25) and compared to carcinoembryonic antigen (CEA), cancer antigen (CA)15-3 and von Willebrand factor antigen (vWF) levels by specificity-sensitivity profiles. Results: LMP, CEA and CA15-3 levels differed significantly between breast cancer patients and controls, whereas EMP and vWF did not. The specificity-sensitivity profiles of LMP and CA15-3 were similar. Conclusion: Increasing levels of circulating LMP(CD45+), CEA and CA15-3 correlated with increasing tumor size, thus reflecting disease stage. LMP showed an equal specificity-sensitivity profile to the established marker CA15-3 and therefore might have the potential to become a new biomarker in breast cancer patients. ER -